Table IV.
Previous treatments
| Previous systemic treatment | Number (%) of patients with previous systemic treatment or not∗ | Type of treatment | Number (%) of administered treatments† | |
|---|---|---|---|---|
| Yes | 305 (83.1) | Phototherapy | UVB | 87 (20.3) |
| PUVA | 49 (11.4) | |||
| Conventional systemic | Cyclosporine | 6 (1.4) | ||
| Fumaric acid | 84 (19.6) | |||
| Methotrexate | 86 (20.1) | |||
| Retinoids | 30 (7.0) | |||
| Biologics | Adalimumab | 16 (3.7) | ||
| Etanercept | 19 (4.4) | |||
| Golimumab | 1 (0.2) | |||
| Infliximab | 2 (0.5) | |||
| Ixekizumab | 1 (0.2) | |||
| Secukinumab | 10 (2.3) | |||
| Ustekinumab | 18 (4.2) | |||
| Other | 19 (4.4) | |||
| Total number of treatments | 428 (100) | |||
| No | 62 (16.9) | NA | NA | |
NA, Not applicable; PUVA, psoralen plus ultraviolet A; UVB, ultraviolet B.
∗
Percentages of patients with (N = 305, 83.1%) and without (N = 62, 16.9%) therapy before starting apremilast.
†
Certain patients received more than one previous treatment; thus the total number of specific treatment (N = 428) for psoriasis exceeds the total number of patients who had received previous treatment.